Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Simultaneous Liver-Kidney Transplant.
- Who it may be relevant to
- Registry conditions: Polyomavirus Infections, BK Viremia, Liver Transplant Infection, Kidney Transplant Infection. Basic parameters: 18 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant Recipients: A Retrospective Single-Center Review
Overview
The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.
Detailed description
The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%. Immunosuppression reduction is the management cornerstone for BKV and has been shown to be effective at clearing the virus while maintaining graft function in both kidney alone and simultaneous kidney-pancreas transplant recipients. However, there is a lack of published data on the prevalence and outcomes in simultaneous liver-kidney (SLK) transplant recipients.
Interventions
- Procedure Simultaneous Liver-Kidney Transplant
Simultaneous Liver-Kidney Transplant
Primary outcome measures
- To characterize the prevalence of BKV in the SLK patient population at (Methodist Dallas Medical Center)MDMC. [Time frame: over a 6-year period (2015 to 2020).]
Eligibility criteria
Inclusion criteria
- Age 18 years or older
- SLK recipients transplanted at MDMC between 2015-2020
Exclusion criteria
- Below 18 years of age
- Patients who did not undergo SLK transplant at MDMC
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-only
Study locations
United States · 1 center
- Methodist Dallas Medical Center — Dallas
Publications
- Kotton CN, Kamar N, Wojciechowski D, Eder M, Hopfer H, Randhawa P, Sester M, Comoli P, Tedesco Silva H, Knoll G, Brennan DC, Trofe-Clark J, Pape L, Axelrod D, Kiberd B, Wong G, Hirsch HH; Transplantation Society International BK Polyomavirus Consensus Group. The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation. Transplantation. 2024 Sep 1;108 PMID 38605438
Identifiers
NCT: NCT05224583 · 052.MTP.2021.D